Nasdaq-100 Index® June 2026 Quarterly Changes

Nasdaq announced the results of its June 2026 quarterly rebalance of the Nasdaq-100 Index, effective June 22, 2026. Five companies were added to the index: Astera Labs, CoreWeave, Nebius Group, Rocket Lab, and Teradyne. Five companies were removed: Charter Communications, Cognizant Technology Solutions, Insmed, Verisk Analytics, and Zscaler.

06/11/2026, 8:00 PM • GlobeNewswire

Nasdaq 100 Climbs Records, Oil Extends Drop As Iran Weighs Hormuz Deal: Stock Market Today

U.S. tech stocks reached record highs on May 7, 2026, as crude oil tumbled nearly 3% on hopes Iran will accept a U.S. memorandum to reopen the Strait of Hormuz. The Nasdaq 100 gained 0.4% to 28,706 while the S&P 500 rose 0.2% to 7,376. Earnings drove significant stock-specific moves, with major winners including AAON (+36%), Datadog (+30%), and H&R Block (+26%), while notable losers included Planet Fitness (-33%), Insmed (-22%), and Zoetis (-22%).

05/07/2026, 12:44 PM • Benzinga

Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight

The interstitial lung disease market is projected to grow at a CAGR of 8.7% from 2026-2036, driven by emerging therapies and pipeline candidates. The market was valued at USD 6 billion in 2025 across seven major markets, with the US accounting for 83% of the market. Key developments include FDA approval of nerandomilast (JASCAYD) for progressive pulmonary fibrosis and multiple late-stage candidates addressing immune dysregulation and fibrotic signaling.

04/08/2026, 1:00 PM • GlobeNewswire

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story

RTW Investments established a new $193 million position in Apellis Pharmaceuticals by acquiring 7.67 million shares in Q4 2025. Despite a 29% stock decline over the past year, the investment signals confidence in the company's commercial-stage biotech portfolio, which generated $689 million in product revenue driven by its flagship therapy. The position represents a calculated pivot toward more durable revenue streams within a portfolio focused on high-growth biotech names.

03/21/2026, 7:19 PM • The Motley Fool

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib

Alumis shares surged 94.53% following positive Phase 3 trial results for envudeucitinib, an oral TYK2 inhibitor for psoriasis that met primary and secondary endpoints. The company announced plans to raise $175 million in capital to support commercialization of the drug and its pipeline. The broader market rose modestly with the S&P 500 gaining 0.62% and Nasdaq up 0.65%.

01/06/2026, 5:12 PM • The Motley Fool

Nike, Insmed, And Arm Are Among Top 10 Large Cap Losers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio?

Ten large-cap stocks experienced significant declines last week. Nike fell 12.81% due to a 17% decline in Greater China sales and analyst downgrades. ARM Holdings dropped 9.77% following Goldman Sachs and Bank of America downgrades. Other major losers included Lennar (9.94% decline after earnings miss), Marathon Petroleum (9.42%), Phillips 66 (8.84%), Coupang (8.52%), BitMine Immersion (9.15%), Insmed (11.37%), Entegris (5.90%), and ServiceNow (0.78%).

12/21/2025, 10:01 AM • Benzinga

Annual Changes to the Nasdaq-100 Index®

Nasdaq announced its annual Nasdaq-100 Index reconstitution, adding six companies and removing six others, effective December 22, 2025. The changes reflect the dynamic composition of leading non-financial companies across various sectors.

12/12/2025, 8:00 PM • GlobeNewswire

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks

Billionaire investor Stanley Druckenmiller has invested 30% of his portfolio in three biotech stocks: Natera, Insmed, and Teva Pharmaceutical Industries, demonstrating strong confidence in the biotech sector's potential.

11/30/2025, 3:14 AM • The Motley Fool

DPP1 Inhibitor Market Set to Reach New Heights in the Coming Decade | DelveInsight

The DPP1 inhibitor market is experiencing significant growth, driven by BRINSUPRI's approval for non-cystic fibrosis bronchiectasis and increasing prevalence of respiratory diseases. Multiple emerging therapies are advancing in clinical trials, with potential to transform treatment landscapes.

09/08/2025, 1:00 PM • GlobeNewswire

Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight

Insmed's BRINSUPRI receives FDA approval as the first therapy for non-cystic fibrosis bronchiectasis, marking a significant breakthrough in treating a condition with high unmet medical needs. The drug targets DPP1 and is expected to generate peak sales of around $5 billion.

08/25/2025, 3:00 PM • GlobeNewswire

Pulmonary Hypertension associated with Interstitial Lung Disease Market to Witness Upsurge in Growth During the Forecast Period (2025–2034) | DelveInsight

The Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market is expected to grow significantly between 2025-2034, driven by improved diagnostic techniques, disease recognition, and emerging therapies targeting functional improvement and disease progression.

08/14/2025, 1:00 PM • GlobeNewswire

Russell Rebalance: 3 Stocks Ready to Move Higher

The article discusses three stocks that could see a price increase due to the upcoming Russell index rebalancing: Sprouts Farmers Market (SFM), Insmed (INSM), and FTAI Aviation (FTAI).

06/20/2025, 1:37 PM • Investing